The purpose of this study was to evaluate from a consumer's perspective the content of digital video advertisements posted on the website YouTube.com. Advertisements for the top-selling 25 prescription drugs were identified during a 1-month time period (September 2009) and were categorized as either regulated or unregulated by the FDA. Unregulated advertisements were further classified as educational (by health care professionals), commercial (to sell drugs or for lawsuit claims), or miscellaneous. Drug name, advertisement type, number of views, and rating by viewers were collected. The current sample consists of 11.4% FDA-regulated and 88.6% FDA-unregulated (15.4% educational, 5.8% commercial, and 88.8% miscellaneous) advertisements. FDA-unregulated advertisement videos had a higher number of average views (6318 + 10,325) compared with FDAregulated videos (6044 + 10,991). As consumers are exposed to a large number of FDA-unregulated advertisements for prescription drugs on YouTube, education is needed to enable consumers to distinguish between FDA-regulated and FDA-unregulated videos.

years were employable and actually employed, respectively. Average HAQ scores at week 24 were 1.08 and 0.92 for MTX and GLM, respectively. Among patients 'unemployable' at baseline, 33% of GLM and 15% of MTX patients became employable at wk24 (pϭ0.04). GLM-treated patients maintained HAQ improvement through wk160 (mean scoreϭ0.88). In logistic regression modeling, for patients with a mean age of 50 years, expected EALYs were 5.92 and 7.15 for female and male GLMtreated patients, compared with 4.96 and 6.28 for female and male MTX-treated patients, an increase of 0.96 (19.2%) and 0.87 (13.8%) EALYs in GLM-treated females and males. Sensitivity analysis demonstrated improvements of 0.81 (16.4%) and 0.74 (11.8%) ELAYs in male and female GLM-treated patients relative to MTXtreated patients. CONCLUSIONS: Results of EALY analysis indicated GLMϩMTXtreated RA patients can realize improvement in employability over time.